Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Robert W. Schrier(University of Denver), Arlene B. Chapman(Emory University), Kaleab Z. Abebe(University of Pittsburgh), Franz T. Winklhofer(University of Kansas), Godela Brosnahan(University of Colorado Denver), Peter G. Czarnecki(Beth Israel Deaconess Medical Center), Frederic F. Rahbari-Oskoui(Emory University), Dana C. Miskulin(Tufts University), Vicente E. Torres(Mayo Clinic in Arizona), Jared J. Grantham(National Institutes of Health), Ronald D. Perrone(Tufts Medical Center), Theodore I. Steinman(Beth Israel Deaconess Medical Center), Marie C. Hogan(Mayo Clinic), William E. Braun(Cleveland Clinic), Charity G. Moore(University of Pittsburgh Medical Center), Kyongtae T. Bae(Mallinckrodt (United States)), Michael F. Flessner, Peter C. Harris(Mayo Clinic)
Cited by 524
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia
|New England Journal of Medicine|2006|1.2k
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Temporal relationships between hormonal and hemodynamic changes in early human pregnancy
|Kidney International|1998|535